

# Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



OMB#: 0925-0648 Exp Date: 7/2027

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

Thank you for attending the 2024 CPTN Virtual Trainee and Scholar Orientation! Please take a few minutes to provide your feedback so we can improve future meetings.

Responses are anonymous. If you would like a response, please contact us at [bpca@infinityconferences.com](mailto:bpca@infinityconferences.com).

All questions are optional, and you may exit the survey at any time.

Please click Next to begin the survey.

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute of Child Health and Human Development



## GENERAL EXPERIENCE

On a scale of 1 to 5, with 5 being the best, how would you rate the orientation experience?

1 (Poor)	2	3	4	5 (Excellent)
★	★	★	★	★

Additional Comments


On a scale of 1 to 5, with 5 being the best, how would you rate the quality of support received during the orientation?

1 (Poor)	2	3	4	5 (Excellent)	N/A
★	★	★	★	★	○

Additional Comments

# Best Pharmaceuticals for Children Act

**NIH** Eunice Kennedy Shriver National Institute of Child Health and Human Development



## AGENDA FEEDBACK

**On a scale of 1 to 5, with 5 being the best, please rate the following sessions:**

### SESSION I: Welcome to NICHD & CPTN

[Overview of the National Institutes of Health (Pawlyk); Getting to Know You/History of the Clinical Pharmacology Training Network & Updates (Samedy-Bates); Getting to Know CPTN & Network Expectations (INFINITY)]

1 (Poor)

2

3

4

5 (Excellent)



Additional Comments

### SESSION II: Navigating the NIH

[NIH Jargon and Acronyms (Bardhan); Working with NIH Program Officers (Popkin); Working with NIH Scientific Review Officers (Robbins); Mock Study Section Review]

1 (Poor)

2

3

4

5 (Excellent)



Additional Comments

### SESSION III: Making the Most of Your Training

[Identifying and Working with a Mentor (Taylor-Zapata); Planning Your Training & Career Development Timeline (Girardi); Novel Training & Career Development Opportunities]

1 (Poor)

2

3

4

5 (Excellent)



Additional Comments

# SESSION IV: More Skills for Successful Investigators


[Data Sharing: Navigating the Data Ecosystem (Vance); The Road to “R”-Land (Pileggi); Fireside Chat: Conversation with Trainee Alumni]

1 (Poor)	2	3	4	5 (Excellent)
★	★	★	★	★

Additional Comments

# Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute  
of Child Health and Human Development



## GENERAL FEEDBACK

On a scale of 1 to 5, what is your overall rating of the 2024 Clinical Pharmacology Training Network (CPTN) Trainee & Scholar Orientation?

1 (Poor)

2

3

4

5 (Excellent)



Additional Comments

Do you feel better prepared/supported in your training career as a result of what you heard at the orientation?

Are there other topics you feel would be beneficial for new trainees to hear about that weren't covered during the orientation?

Please provide any additional comments regarding the hybrid meeting format, agenda content, or logistical support.

Thank you for your feedback! As a reminder, all responses are anonymous. If you would like a response to your comments, please reach out via email to [bpca@infinityconferences.com](mailto:bpca@infinityconferences.com).